Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.
14 Janeiro 2022 - 9:30AM
Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, is pleased to announce that through its
majority owned subsidiary Santa Marta Golden Hemp (“SMGH”) the
company has entered into a Master Supply Agreement with established
Chilean pharmaceutical company Knop Laboratorios S.A. (“Knop”) to
supply a range of cannabinoid-based active pharmaceutical
ingredients (“API”) for the manufacturing, and commercialization of
proprietary cannabinoid-based pharmaceutical products in Latin
America.
Since 2018, Avicanna and Knop have developed a
collaborative enterprise which has led to commercial imports of
Avicanna´s API, including CBD and THC, which has been used in the
development, production and commercialization of several
cannabinoid-based products. Through this Master Supply Agreement
between SMGH and Knop the two companies are further fortifying
their commitments to a fruitful partnership and preparing for
industrialization of Knop’s cannabinoid-based pharmaceuticals
manufactured using Avicanna’s organic, sustainable inputs.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e298f331-9e1a-46af-af2a-e7dd7a620ad4
About Knop Laboratorios
S.A.
Knop Laboratorios S.A. is a Chilean
pharmaceutical company and pioneer in herbal medicine with more
than 90 years of experience in the field and active presence in
several Latin American countries including Chile, Ecuador,
Colombia, Bolivia, Paraguay, and Peru. With a GMP certified plant
located in Quilpué, Chile, Knop Laboratorios serves its markets
with high-quality pharmaceutical products. Knop has a wide
portfolio of registered products, including Cannabiol®, a
cannabinoid-based product already registered in Perú, and its own
commercial infrastructure including strategic partnerships with 80+
“Knop Pharmacies” in Chile. In 2021, Knop opened the first R&D
Center in Chile for phytomedicines and active ingredients of
natural origin.
Knop is carrying out various Clinical Studies
for their cannabinoid-based products, with authorization from the
appropriate health authorities.
“We are happy to announce the fortification of
our partnership with Knop and further expand into the Chilean
market through our active pharmaceutical ingredient (API) offerings
with an established pharmaceutical leader and pioneer in the
cannabinoid sector in Chile. Over the past few years, we have
worked closely together and are thrilled about the potential of
what the two companies can accomplish jointly in the emerging
medical and pharmaceutical industry, of the Southern Cone of Latin
America.” stated Lucas Nosiglia, President of Avicanna LATAM.
About Avicanna
Avicanna is a Canadian commercial-stage
biopharmaceutical company established in cannabinoid research,
development, and evidence-based products for the global consumer,
as well as medical and pharmaceutical market segments. In leading
global cannabinoid advancements, Avicanna conducts most of its
research in Canada at its R&D headquarters in the Johnson &
Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS
Discovery District. The company actively collaborates with leading
Canadian academic and medical institutions. Avicanna has
established an industry-leading scientific platform including
advanced R&D and clinical development which has led to the
commercialization of over twenty products across four main market
segments:
- Medical Cannabis
& Wellness Products: Marketed under the RHO Phyto™ brand, or
Magisterial Preparations, these medical and wellness products are
an advanced line of pharmaceutical-grade cannabis products
containing varying ratios of cannabidiol (“CBD”) and
tetrahydrocannabinol (“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and
medical community education and training. Avicanna’s medical and
wellness product portfolio also forms the foundation of the
Company’s pharmaceutical pipeline with the contribution of the
formulations that form the basis of the products as well as the
data generated from sales and participation of the products in real
world evidence studies.
- CBD
Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura
Earth™ brands, these registered, clinically tested, derma-cosmetic
products include a portfolio of functional CBD topical
products.
- Pharmaceutical
Pipeline: Leveraging Avicanna’s scientific platform, vertical
integration, and real-world evidence, Avicanna has created a
pipeline of patent-pending drug candidates which are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates
provide solutions for unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox) is in the
drug registration stage in South America.
- Cannabis Raw
Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™
brand, the Company’s raw material business has successfully
completed sales to 11 countries. Aureus offers cannabis dried
flower, standardized seeds, full spectrum extracts, and cannabinoid
distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”)
and other rare cannabinoids), and bulk formulations derived from
hemp and cannabis cultivars through its sustainable, economical,
and industrial-scale subsidiaries based in Colombia. The majority
of the Aureus products are produced at Santa Marta Golden Hemp
S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is
also Good Agricultural and Collection Practices (“GACP”) certified
and has United States Department of Agriculture (“USDA”) National
Organic Program certification for its hemp cultivar.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com,
contact Ivana Maric by email at info@avicanna.com or follow us on
social media on LinkedIn, Twitter, Facebook or Instagram.
The Company posts updates through videos from the official
company YouTube channel
https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding Forward-Looking Information
and Statements
This news release contains "forward-looking
information" within the meaning of applicable securities laws.
Forward-looking information contained in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions. Forward-looking information is not a guarantee
of future performance and is based upon a number of estimates and
assumptions of management in light of management's experience and
perception of trends, current conditions and expected developments,
as well as other factors relevant in the circumstances, including
assumptions in respect of current and future market conditions, the
current and future regulatory environment, the availability of
licenses, approvals and permits, and the utility and potential
application of certain drugs, cannabinoids, compounds and products.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include, but are not limited to
current and future market conditions, including the market price of
the common shares of the Company, and the risk factors set out in
the Company's annual information form dated September 3, 2021 and
final short form prospectus dated November 27, 2020, filed with the
Canadian securities regulators and available under the Company's
profile on SEDAR at www.sedar.com. The statements in this press
release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
securities laws.
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Avicanna (TSX:AVCN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024